Clinical trial
Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic…
NCT00270205 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00270205 |
|---|---|
| Title | Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART |
| Official title | A Phase I/II, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of LC002, a DermaVir Vaccine, in HIV-1-Infected Subjects Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART) |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Biological |
| Interventions | LC002 standard vaccination, LC002 high-dose vaccination, LC002 placebo vaccination |
| Enrollment | 28 |
| Start date | Jan 1, 2006 |
| Primary completion | Sep 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Dec 26, 2005 |
| Last update posted | Nov 4, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: